Diagnosis of autoimmune central diabetes insipidus (CDI) is
(58.3%) in group 1b were positive for AVPcAb and persisted positive subsequently, during all the follow-up period, even if at lower titers. All patients in group 2 were positive and all those in group 3 were negative for AVPcAb and persisted positive and negative, respectively, for all the follow-up study. Among the AVPcAb-positive patients, only 5 in group 1a and 2 in group 2 showed also pituitary stalk thickening at the first observations, which however spontaneously disappeared subsequently indicating a possible lymphocytic infundibuloneurohypophysitis. All patients in the studied groups showed loss of the hyperintense signal of the neurohypophysis on MRI at entry and during all the follow-up period. Results of this longitudinal study suggest: 1) AVPcAb, frequently present at high titers in recent phases of CDI, persist subsequently, even if at lower titers, several years after the onset of disease. 2) The occurrence of a lymphocytic infundibulo-neurohypophysitis suggested by the pituitary stalk thickening on MRI only in patients positive for AVPcAb confirms a further autoimmune variant of CDI also in these cases.
3) The longitudinal behavior of patients in group 3 suggests that the absence of AVPcAb at the onset of clinical idiopathic CDI is able to exclude a subsequent appearance of these antibodies and consequently an autoimmune involvement in CDI of these patients. Instead the finding of AVPcAb in several patients with only CDI, thought at first clinical observation as idiopathic, indicates that the prevalence of autoimmune CDI must be considered much higher than that so far reported. (J Clin Endocrinol Metab 87: 3825-3829, 2002) C ENTRAL DIABETES INSIPIDUS (CDI) may be familial or secondary to injury toward the hypothalamicinfundibulo-neurohypophyseal system (1) (2) (3) (4) . Frequently an organic lesion in this region may be due to inflammatory diseases, as Langherans-cell histiocytosis, sarcoidosis, tubercolosis or autoimmune process (5) . In absence of all the above mentioned ethiological factors, CDI is usually classified as idiopathic. Imura et al. (6) showed that autoimmune CDI could be due to a lymphocytic infundibulo-neurohypophysitis revealed by infiltration of lymphocytes and plasma-cells on biopsy samples of pituitary stalk and/or suggested by the presence of isolated pituitary stalk thickening on magnetic resonance imaging (MRI), which can disappear over time spontaneously or after corticosteroid therapy. However, in these patients antibodies to AVP-secreting cells (AVPcAb) have not been studied. Moreover, the frequent association between CDI and clinical or subclinical autoimmune endocrine diseases, the possible presence of AVPcAb, not only in patients with clinical CDI but also in those with autoimmune polyendocrine syndromes (APS) without CDI, suggested an autoimmune variant of this disease (7) (8) (9) (10) (11) (12) . So far, in clinical CDI patients with or without APS, longitudinal studies on the behavior of AVPcAb, as well as on the relationship between AVPcAb and hypothalamic-pituitary imaging on MRI have not been performed. The aim of this longitudinal study in patients with complete CDI with APS and in those with complete idiopathic CDI was 2-fold: first, to inAbbreviations: APS, Autoimmune polyendocrine syndromes; AVPcAb, AVP-secreting cells; CDI, central diabetes insipidus; MRI, magnetic resonance imaging.
vestigate the presence of AVPcAb and pituitary stalk thickening on MRI; second, to evaluate longitudinally if any change of these findings occurs during a long-term follow-up.
Subjects and Methods
On the basis of an AVPcAb screening, performed since 1993 in a large cohort of 2385 patients with APS, 22 patients with complete autoimmune CDI were enrolled in this study. Diagnosis of autoimmune complete CDI was done on the basis of its association with APS and of respective organ specific autoantibodies in presence or absence of AVPcAb. On the basis of duration of autoimmune complete CDI these patients were grouped as follows: group 1a, consisting of 10 patients (8F, 2M, aged 29 -36 yr) with recent onset of CDI (Յ 1.5 yr, range 0.5-1.4 yr); group 1b, consisting of 12 patients (9F, 3M, aged 37-53 yr) with CDI of long-term duration (Ն 7 yr, range 7-22 yr). Moreover, 13 patients with apparent idiopathic CDI were also studied; on the basis of the results of AVPcAb they were grouped as follows: group 2, consisting of 5 patients positive for AVPcAb (all females, aged 19 -26 yr) thus considered affected by isolated autoimmune CDI, and group 3, consisting of 8 patients negative for AVPcAb (5F, 3M, aged 21-26 yr) considered as true idiopathic complete CDI also because a familial or secondary CDI was excluded.
All patients were under desmopressin-acetate treatment. At the first observation (off treatment) the diagnosis of CDI had been done on the basis of clinical and laboratory findings according to the accepted criteria (5) . In particular, in all patients of all groups studied, after fluid deprivation, urine and plasma osmolality were less than 300 and 300 milliosmoles/kg or greater, respectively; after desmopressin, urine osmolality was more than 750 milliosmoles/kg.
At study entry, 8 of 10 patients in group 1a and 7 of 12 in group 1b were positive for AVPcAb. As regards to the presence of APS, in group 1a, 5 patients presented with Hashimoto's thyroiditis isolated or associated with Addison's disease, atrophic gastritis and vitiligo, two with Addison's disease and type 1 diabetes mellitus, two with Graves' disease alone and one associated to Addison's disease and premature ovarian failure; in group 1b, eight patients presented with Hashimoto's thyroiditis isolated or associated with premature ovarian failure, atrophic gastritis, celiac disease and vitiligo, 2 with Addison's disease isolated or associated to type 1 diabetes mellitus, 1 with Graves' disease, and 1 with diabetes mellitus. In all patient groups, the respective organ specific autoantibodies were also present.
Patients with hypothyroid Hashimoto's thyroiditis, Addison's disease, and type 1 diabetes mellitus received appropriate replacement therapy; hyperthyroid Graves' patients received antithyroid drugs. All subjects gave their informed consent to the study, which was approved by local ethical committee.
As regards to organ-specific antibodies, islet cell antibodies, adrenal cortex antibodies, parietal cell antibodies, steroid-secreting cell antibodies, endomisial antibodies by indirect immunofluorescence, 21-hydroxylase antibodies, glutamic acid decarboxylase antibodies, thyrotrophin receptor antibodies, thyroglobulin antibodies, thyroperoxidase antibodies, by RIA, were investigated as previously described (13) (14) (15) (16) .
Hormonal pituitary function was also appropriately investigated in all patients of all groups. In particular, basal anterior pituitary hormones were evaluated in duplicate: ACTH, GH, TSH, FSH, LH, and prolactin were determined by immunoradiometric assay method, using commercial kits supplied by CIS (Saluggia, Italy). Moreover dynamic behavior of these hormones was also studied by testing their response to CRH, TRH, GnRH, and GHRH stimuli.
Follow-up study
In all patients AVPcAb and hypothalamic-pituitary region on MRI were evaluated yearly for 5 yr.
Autoantibodies to AVPcAb
AVPcAb were detected by immunofluorescence method on cryostat sections of young baboon hypothalamus, as described previously (11, 12) . In particular, fluorescein isothiocyanate-conjugated goat antihuman Ig sera were used to detect the presence of antibodies to hypothalamic cells, and then positive serum samples were tested with fluorescein isothiocyanate goat antihuman IgG, IgM and IgA sera separately. The specificity of the reaction to vasopressin cells was demonstrated with a four-layer double fluorochrome immunefluorescence test in which the second sandwich consisted of rabbit antivasopressin and antioxitocine sera reacting with rhodamin-labeled goat antirabbit Ig (7). Levels of AVPcAb, considered positive starting at dilution 1/2, were expressed as end-point dilution titer.
One hundred healthy subjects matched for sex and years were used as negative control for AVPcAb.
MRI studies
An MRI of hypothalamic-pituitary region was performed by a 0.5 T Vectra scanner (General Electric, Milwaukee, WI) using T1 weighted gradient echo acquisitions (repetition time
The evaluation of the MRI was performed twice by one operator (F.D.S.) blind in respect to the etiology of CDI of patients of the current study.
MRI evaluation included the detection of neurohypophyseal bright spot (presence or absence) and of transverse dimension of pituitary stalk (17) . We considered the upper limit of normal maximum transverse stalk dimension of 3.3 mm. according to Simmons et al. (17) with some modifications on the basis of our control group data. Pituitary stalk thickening was graded as minimally thickened (from 3.4 -4.5 mm), moderately thickened (from 4.6 -6.5 mm) or severely thickened (more than 6.5 mm) according to Maghnie et al. (18) with minor modifications.
Statistical analysis
Statistical significance of AVPcAb titer and pituitary stalk thickening variations in antibody-positive patient groups at all times of observation were calculated by ANOVA. AVPcAb titers in all patient groups at all times of observation were correlated to the presence of pituitary stalk thickening by the Spearman's test. In all tests, a P value less than 0.05 was considered significant.
Results
None of patients in all groups showed impairment of pituitary hormonal function, but all of them showed loss of the posterior pituitary hyperintense signal on MRI during all the follow-up periods (data not shown).
Variations of AVPcAb titers and of MRI scans of pituitary stalk during the follow-up period are summarized for group 1 (1a and 1b) in Table 1 and for groups 2 and 3 in Table 2 , respectively.
AVPcAb behavior
AVPcAb (all of class IgG) were found in 8 of 10 patients (80%) in group 1a and in 7 of 12 patients (58.3%) in group 1b, with titers ranging from 1/32 to 1/8 and from 1/8 to 1/2, respectively (Table 1) . Subsequently, during the follow-up period, AVPcAb were persistently present in all previously AVPcAb-positive patients of both groups, even if at lower titers ranging finally from 1/8 to 1/4 in group 1a and from 1/4 to 1/2 in group 1b, respectively ( Table 1) ; P value was less than 0.008 with respect to the starting titers only in group 1a (not shown in table). All patients in group 2, initially AVPcAb positive at study entry, with titers ranging from 1/32 to 1/8, persisted positive for all the follow-up even if at lower titers ( Table 2) ; P value was less than 0.01 with respect to the starting titers (not shown in table). Two of them during the follow-up became positive for thyroglobin antibodies and thyroperoxidase antibodies developing subsequently an autoimmune thyroiditis. All AVPcAb-negative patients at study entry in groups 1a, 1b (Table 1) , and in group 3 (Table 2) persisted constantly negative at later subsequent observations. None of them showed other organspecific antibodies or autoimmune endocrine diseases.
MRI findings
As shown in Table 1 , in group 1a pituitary stalk thickening was observed in 3 of the 8 AVPcAb-positive patients at start of the study and in other 2 patients 1 yr after the first MRI observation. In particular, in all 5 patients total stalk was involved, pituitary stalk was minimally or moderately thickened especially after the administration of gadolinium. Subsequently, pituitary stalk thickening markedly improved over time in all patients during the follow-up with a signif- icantly complete reversal at the end of the study (Table 1) . P value was less than 0.006 with respect to the starting values (not shown in table) . In group 2, one patient at start of study, and another, 1 yr after the first observation, showed pituitary stalk thickening which subsequently decreased progressively until normalization at the last observation ( Table 2) . None of patients in group 1b (Table 1 ) and in group 3 ( Table 2) showed pituitary stalk thickening during the study span. A positive correlation between AVPcAb titers and pituitary stalk thickening was found in group 1a initially (r ϭ 0.89; P ϭ 0.000) and at all times of observation until to end of the study (r ϭ 0.86; P ϭ 0.01) and in group 2 only at the first observation (r ϭ 0.91; P ϭ 0.02).
Discussion
Sherbaum et al. (10) showed that some cases of CDI in adult people may be part of APS, in which well established autoimmune diseases may be associated clinically or serologically with CDI, suggesting the concept of an autoimmune pathogenesis of this disease in a subgroup with defined pathological findings. Patients with APS are a good source for the detection of various organ-specific autoantibodies as islet cell antibodies and glutamic acid decarboxylase antibodies in type 1 diabetes mellitus, adrenal cortex antibodies and 21-hydroxylase antibodies in autoimmune Addison's disease (14, 15) , and also AVPcAb in autoimmune CDI (19, 20) . In a previous study, it has been shown in a single patient with autoimmune CDI a decrease in titers of AVPcAb during the follow-up, suggesting that these antibodies may disappear over the years, indicating the necessity of longitudinal studies to clarify this question (10) . So far, longitudinal studies about changes of AVPcAb levels over time in the literature are lacking, except for our study on the longitudinal behavior of AVPcAb in subclinical autoimmune CDI patients (12) . In the present study, we investigated the time course of AVPcAb in patients with clinical autoimmune CDI with and without APS and in those with idiopathic complete CDI. In fact, even if these antibodies do not play a pathogenetic role in autoimmune CDI, so far they can be considered a good serological marker of autoimmune CDI (12) . Our study demonstrated that AVPcAb persist over time during the follow-up period in previous AVPcAb positive patients with or without other autoimmune diseases, including those with a long duration of disease. This persistence, in the absence of functional activity of target cells, could depend on the presence of residual cells unable to function, but still able to present antigens to the immune system.
Another important point of this study is the longitudinal behavior of patients in group 3, suggesting that the absence of AVPcAb at the onset of clinical idiopathic CDI is able to exclude a subsequent appearance of these antibodies and consequently an autoimmune involvement in CDI of these patients.
It has been observed that lymphocytic infundibuloneurohypophysitis in CDI patients can be evidenced by a pituitary stalk biopsy able to reveal a lymphocytic plasmacell infiltration, or suggested by MRI scans able to reveal a pituitary stalk thickening, which can disappear over time spontaneously or after corticosteroid therapy (6, (21) (22) (23) (24) . However, pituitary stalk biopsy is usually reserved to patients with severe and progressive thickening, but not to those with minimal or moderate thickening, as occurring in our patients (18, 25) . The presence of lymphocytic infundibulo-neurohypophysitis in these patients can be suggested by the presence of both pituitary stalk thickening and AVPcAb with or without other subclinical and clinical autoimmune diseases. Pituitary stalk thickening was observed in some autoimmune complete CDI patients with short duration of disease but not in those with long duration of disease or in those with idiopathic CDI. Interestingly, pituitary stalk thickening was present in AVPcAb-positive but not in AVPcAb-negative patients, indicating a strong relationship between the occurrence of these antibodies, markers of autoimmune hypothalamic involvement, and the lymphocytic infundibulo-neurohypophysitis. This is in favor of a further autoimmune variant of CDI also in these cases, even if the lack of histological findings suggests caution against this assumption. However, these results, together with the finding of AVPcAb in several patients with only CDI, thought at first clinical observation as idiopathic, indicates that the prevalence of autoimmune CDI must be considered much higher than that so far reported.
